Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China

Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy.
* Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1.
* Life expectancy of at least 12 weeks.
* No immuno deficiency.
* Adequate organ system function, defined as follows:

  * Absolute neutrophil count (ANC) ≥1.5 x 10\*\*9/L
  * Platelets ≥100 x 10\*\*9/L
  * Hemoglobin ≥10 g/dL
  * Total bilirubin ≤1.5 times the upper limit of normal (ULN)
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤2.5x the upper limit of normal with liver involvement.
  * Creatinine ≤ 1.5 x ULN.
* At least 4 weeks or 5 half-life after receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization.
* Willingness and ability to comply with trial and follow-up procedures.
* Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

* Not recovered from prior anti-cancer therapy or surgery.
* Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks.
* Concomitant use of drugs with a risk of causing prolonged corrected QT interval and/or Torsades de Pointes.
* Patients with a history of intolerance to, or significant toxicity with, VEGFR tyrosine kinase inhibitor(s) (TKI).
* Females who are pregnant or breastfeeding.
* Those in reproductive ages who refuse to use contraception.
* Those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol.
* Patients with known central nervous system (CNS) metastases.
* Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM082 (X-82).
* Patients with known GI disorders such as vomiting, diarrhea.
* Patients who are hepatitis B virus positive.
* Drug abuser.